Hsu TC - Search Results

1

Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.

Hsu TC, Wang CC. Hsu TC, et al. J Comp Eff Res. 2019 Jan;8(2):73-79. doi: 10.2217/cer-2018-0078. Epub 2018 Dec 18. J Comp Eff Res. 2019. PMID: 30560687 Free article.

2

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.

Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT. Hsu TC, et al. Value Health. 2011 Jul-Aug;14(5):647-51. doi: 10.1016/j.jval.2011.01.010. Epub 2011 Jun 22. Value Health. 2011. PMID: 21839401 Free article.

3

Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer.

Hsieh CH, Chen YJ, Chang KH, Hsu HH, Liu CK, Hung SK, Chen HW, Lai YL, Hsu TC. Hsieh CH, et al. Among authors: hsu hh, hsu tc. Anticancer Res. 2006 Sep-Oct;26(5B):3709-15. Anticancer Res. 2006. PMID: 17094389 Free article.

4

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan.

Yeh KH, Yang TS, Hsu TC, Tzu-Liang Chen W, Chen HH, Teng HW, Lin BW, Kuan FC, Chiang FF, Duann CW, Li YS, Lin MT, Fiala-Buskies S, Ducreux M, Wang JY. Yeh KH, et al. Among authors: hsu tc. J Formos Med Assoc. 2021 Nov;120(11):2023-2031. doi: 10.1016/j.jfma.2020.12.015. Epub 2021 Jan 7. J Formos Med Assoc. 2021. PMID: 33422398 Free article.

5

Unusual elevation of CEA in a patient with history of colon cancer.

Hsu TC. Hsu TC. Jpn J Clin Oncol. 2006 Dec;36(12):811-3. doi: 10.1093/jjco/hyl110. Epub 2006 Oct 23. Jpn J Clin Oncol. 2006. PMID: 17060406

6

An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan.

Lee KD, Chen HH, Wang HM, Tsao CJ, Hsu TC, Chiu CF, Su WC, Wang JY. Lee KD, et al. Among authors: hsu tc. Oncology. 2013;84(5):299-304. doi: 10.1159/000347228. Epub 2013 Mar 16. Oncology. 2013. PMID: 23548831

7

TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer.

Hsu TC. Hsu TC. Oncol Lett. 2015 Mar;9(3):1059-1064. doi: 10.3892/ol.2015.2855. Epub 2015 Jan 7. Oncol Lett. 2015. PMID: 25663857 Free PMC article.

8

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study.

Chang CW, Wei SC, Chou JW, Hsu TC, Chuang CH, Lin CP, Hsu WH, Yen HH, Lin JK, Fang YJ, Wang HY, Lin HH, Wu DC, Ni YH, Wang CY, Wong JM. Chang CW, et al. Among authors: hsu wh, hsu tc. Intest Res. 2014 Oct;12(4):287-92. doi: 10.5217/ir.2014.12.4.287. Epub 2014 Oct 27. Intest Res. 2014. PMID: 25374494 Free PMC article.

9

Comparison of tolerance and change of intragastric pH between early nasogastric and nasojejunal feeding following resection of colorectal cancer.

Hsu TC, Su CF, Huang PC, Lu SC, Tsai SL. Hsu TC, et al. Clin Nutr. 2006 Aug;25(4):681-6. doi: 10.1016/j.clnu.2005.12.011. Epub 2006 May 15. Clin Nutr. 2006. PMID: 16698136 Clinical Trial.

10

A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease.

Lin CC, Wei SC, Lin BR, Tsai WS, Chen JS, Hsu TC, Lin WC, Huang TY, Chao TH, Lin HH, Wong JM, Lin JK. Lin CC, et al. Among authors: hsu tc. Intest Res. 2016 Jul;14(3):248-57. doi: 10.5217/ir.2016.14.3.248. Epub 2016 Jun 27. Intest Res. 2016. PMID: 27433147 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

721 results

Search Page